细胞癌 (RCC) 的辅助疗法:进展,最后
Andrew N Bueno1, Mark N Stein2, Karie Runcie2
1Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Translational cancer research
|December 19, 2024
概括
辅助 pembrolizumab 现在是手术后高风险清细胞细胞癌 (ccRCC) 的标准治疗方法,显著改善了存活率. 这标志着治疗癌复发后切除术的新时代.
科学领域:
- 在瘤学瘤学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫治疗是一种免疫疗法.
背景情况:
- 细胞癌 (RCC) 每年影响成千上万,局部性疾病通常通过切除术治疗.
- 手术后,多达50%的患者面临复发,需要有效的辅助疗法.
- 之前在RCC中的辅助治疗在很大程度上未能显示出显著的临床益处.
研究的目的:
- 审查细胞癌 (RCC) 中的主要辅助临床试验,重点关注清细胞RCC (ccRCC).
- 突出免疫检查点抑制剂 (ICI) 在辅助剂环境中的影响.
- 提供高风险局部cccRCC经切除术后的管理框架.
主要方法:
- 对RCC中关键辅助剂临床试验的审查,包括KEYNOTE-564.
- 对测试的治疗药物的分析,如细胞因子,疫苗,VEGF抑制剂,mTOR抑制剂和ICI.
- 专注于高风险ccRCC患者的无进展和整体生存数据.
主要成果:
- 基诺特-564试验表明,辅助布罗利祖马布显著改善了无进展的生存率.
- 辅助布罗利祖马布最近还显示,高风险ccRCC患者的整体存活率有好处.
- 这些结果确立了辅助 pembrolizumab 作为一种新的护理标准.
结论:
- 辅助药布罗利祖马布在切除术后管理高风险的ccRCC方面取得了突破.
- 这标志着减少癌复发的重大进展.
- 基于试验证据,提出了管理这些患者的框架.
更多相关视频
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:27Tumor Immunotherapy
475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475